Proventa International will be gathering over 100 C-Level Directors from a mix of emerging to large Pharmaceutical, Biotechnology & Academic/Research Institutions to help solve their key strategic challenges in the area of Oncology.Register Now
The Oncology Roundtable Discussions Strategy Meeting is free to attend for qualified end-users. These include Senior Executives of Oncology/Immuno-Oncology (from medium to large Pharma, Biopharma and Biotech players) in global development positions spanning early development to phase IV, as well as thought leaders from Academia and regulatory authorities.
Thought leaders who will benefit from attending include CXOs, EVPs, SVPs, VPs, Executive Directors, Directors and Global Heads responsible for:
– Oncology R&D,Translational Research/Development/Medicine, Clinical Research/Development, Immuno-Oncology, Medical Affairs Oncology,Clinical Pharmacology,Oncology Clinical Biostatistics and Programming, Oncology Clinical Genomics and Computational Biology, Oncology R&D Innovation, Oncology R&D Strategy, Oncology Portfolio/Project Management.
Those who do not qualify for complimentary passes, including vendors, exchanges, consultancies and other service providers, can apply here.
Executive Vice President and Chief Medical Officer Head of Business Development
President and Chief Medical Officer, Kyowa Kirin Pharmaceutical Development, Inc.
Executive Vice President and Chief Medical Officer Head of Business Development, BeyondSpring Pharmaceuticals
Established Oncology Products for Novartis where he managed all clinical and regulatory maintenance work for the division, which represented total annual revenue of approximately $2 billion. He also developed immunooncology development programs based on checkpoint inhibitor combination therapy at AstraZeneca. Prior, he held positions with Interleukin Genetics as Chief Medical Officer and Vertex Pharmaceuticals as Medical Director. He has also obtained extensive licensing and deal-making experience at Syntium Inc.
Senior Vice President and Chief Medical Officer, Constellation Pharmaceuticals
Vice President, Clinical Operations, Mersana Therapeutics
Vice President & Head Early Development, Strategy and Innovation, Novartis
Vice President, Team Leadership & Head of Precision Medicine, Ignyta
Associate Vice President, Global Head of Biostatistics, Oncology, Sanofi
Zhenming has been involved in multiple PhRMA working groups, including PFS and Clinical Trial Advocacy groups. Zhenming is the author of many publications, and presentations, on influential statistical and medical journals and professional conferences / workshops. His statistical research interests include adaptive designs in clinical trials, longitudinal data and categorical data, random effect models.
Zhenming received his Ph.D. in statistics from the University of Chicago.
Executive Director, Harvard University office of Technology Development
President & Chief Medical Officer
Kwoya Kirin Pharmaceutical Development Inc.
at the Johns Hopkins Hospital. He has served as Chief Oncology Fellow at the US NIH National Cancer Institute and has co-authored multiple peer-reviewed publications, book chapters, and a patent.
Research & Development, MedImmune
Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since 1992. Rakesh served as a Senior Toxicologist with Midwest Research Institute between 1987 and 1992.
In December 1992, Rakesh joined the Department of Safety Assessment, Merck and Co., Inc, West Point, PA where he served in various management positions. During his about 14 years with Merck, Rakesh contributed to the successful filings of many blockbuster drugs. For about a year, Rakesh was associated with Johnson and Johnson PRD, La Jolla/Alza as Senior Director of Toxicology.
In Aug 2006, Rakesh joined MedImmune, Inc. (an AstraZeneca Biologics company) as Senior Director (R &D) & Global Head of Biologics Safety Assessment, Experimental Pathology, and Laboratory Animal Medicine. In his current position as a Vice President of R &D since 2010, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines. Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings. Rakesh is one of the most invited speakers in the biotechnology industry.
Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications.. Rakesh is the Editor-in- chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.
Oncology Strategy Meeting USA East Coast 2016,
The Westin Boston Waterfront
425 Summer St, Boston, MA 02210